I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients

Phase 4 Completed 1630 enrolled Sanofi Bristol-Myers Squibb · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

* To evaluate control rate of Blood Pressure ≤ 140/90 mm Hg in non-diabetic patients, and ≤ 130/80 mm Hg in diabetic patients. * To determine percentage of patients achieving blood pressure control according to their profile (naïve, switch, patient history, etc…) at the end of the trial.

Timeline

Start: 2006-02
Primary completion: 2006-11
Completion: 2006-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Hydrochlorothiazide	Unknown	12.5 mg	Oral
Subject	Irbesartan	Small molecule	150 mg	Oral
Subject	Irbesartan	Small molecule	300 mg	Oral

I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients

Summary

Timeline

Drugs

Indications